tbuckley/cabot-search huggingface dataset:
A retrospective impact analysis of the WannaCry cyberattack on the NHS
Authors: S. Ghafur, S. Kristensen, K. Honeyford, G. Martin, A. Darzi, P. Aylin
Journal: npj Digital Medicine (2019)

A systematic analysis of Hospital Episodes Statistics (HES) data was done to determine the effects of the 2017 WannaCry attack on the National Health Service (NHS) by identifying the missed appointments, deaths, and fiscal costs attributable to the ransomware attack. The main outcomes measured were: outpatient appointments cancelled, elective and emergency admissions to hospitals, accident and emergency (A&E) attendances, and deaths in A&E. Compared with the baseline, there was no significant difference in the total activity across all trusts during the week of the WannaCry attack. Trusts had 1% more emergency admissions and 1% fewer A&E attendances per day during the WannaCry week compared with baseline. Hospitals directly infected with the ransomware, however, had significantly fewer emergency and elective admissions: a decrease of about 6% in total admissions per infected hospital per day was observed, with 4% fewer emergency admissions and 9% fewer elective admissions. No difference in mortality was noted. The total economic value of the lower activity at the infected trusts during this time was £5.9 m including £4 m in lost inpatient admissions, £0.6 m from lost A&E activity, and £1.3 m from cancelled outpatient appointments. Among hospitals infected with WannaCry ransomware, there was a significant decrease in the number of attendances and admissions, which corresponded to £5.9 m in lost hospital activity. There was no increase in mortality reported, though this is a crude measure of patient harm. Further work is needed to appreciate the impact of a cyberattack or IT failure on care delivery and patient safety.
Signs of immunosenescence in patients diagnosed with non-small cell lung cancer
Authors: T. Soria Comes, V. Palomar-Abril, M. Martin Ureste, J.E. Marco Buades, M.J. Fernandez Llavador, J. Garcia Sanchez, M.D.C. Cancela Gomez, I. Maestu Maiques
Journal: Annals of Oncology (2018)

Background: Lately, there has been a great evolution of immunotherapy in non-small cell lung cancer (NSCLC) due to its relationship with inflammation. There is also a growing interest in the changes produced in immune system with age (immunosenescence). However, it is unclear if these differences also exist among elderly patients with cancer compared to adult patients with the same diagnosis and this is the aim of our study. Methods: We retrospectively studied patients diagnosed of NSCLC during January-December 2017 at the time of diagnosis, excluding patients with chronic infections or autoimmune diseases. Included cases were divided into two groups depending on age. Lymphocyte count by flow cytometry was gathered at baseline and we studied if there were statistically significant differences in lymphocyte populations between young (<70) and elderly patients (≥70). The non-parametric Mann-Whitney test was used. Results: 81 patients were analysed; 32 in the young group and 49 in the elderly group. Regarding the innate immunity, the median value of NK lymphocytes showed to be higher in the cohort of patients ≥70 years (295 vs 191 cells/mm3; p = 0.0014). Oppositely, the median value of B-lymphocytes was lower in elderly patients (99 vs 128 cells/mm3; p = 0.0282). The Spearman coefficient for the correlation between age and B-lymphocyte count supports this data: ρ = 0.36 (moderate association). However, there was no difference between the median values of T-lymphocytes (p = 0.142). Interestingly, analysing T-lymphocyte subsets we found that median CD8 value was higher in the elderly group (464 vs 309.5 cells/mm3; p = 0.0226) but there was no difference in the CD4-lymphocyte subset (p = 0.4928). Conclusions: Our results are similar to the ones reported in non-oncologic population, such as an increased number of NK-lymphocytes in elderly patients and a lower count of B-lymphocytes. Therefore, signs of immunosenescence can be seen in patients with NSCLC. However, subpopulations of lymphocytes show more accurately cell functionality. This is why we are performing deeper research regarding the changes in immune system produced with age in oncologic patients. Legal entity responsible for the study: Doctor Peset University Hospital. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Alpelisib (ALP) + endocrine therapy (ET) by last prior therapy in patients (pts) with PIK3CA-mutated hormone-receptor positive (HR+) human epidermal growth factor receptor-2-Negative (HER2–) advanced breast cancer (ABC): Additional study cohort in BYLieve
Authors: E. Ciruelos, F. Lerebours, M. Ruiz Borrego, T. Bachelot, J. Polikoff, S. Chia, D. Juric, N. Turner, A. Ridolfi, N. Sophos, B. Cooper, A. Thuerigen, H.S. Rugo
Journal: Annals of Oncology (2019)
Phase II study of pertuzumab and trastuzumab-emtansine (T-DM1) in patients with HER2-positive metastatic colorectal cancer: The HERACLES-B (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification, cohort B) trial
Authors: A. Sartore-Bianchi, C. Martino, S. Lonardi, E. Fenocchio, A. Amatu, S. Ghezzi, V. Zagonel, F. Ciardiello, A. Ardizzoni, F. Tosi, E. Valtorta, V. Torri, E. Bonoldi, A. Sapino, A. Bardelli, G. Cappello, A. Vanzulli, S. Marsoni, L. Trusolino, S. Siena
Journal: Annals of Oncology (2019)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: Results of single arm phase IV COMACHI study
Authors: N. Masuda, S. Ohtani, S. Nagai, S. Takashima, M. Yamaguchi, M. Tsuneizumi, Y. Komoike, T. Osako, Y. Ito, M. Ikeda, K. Ishida, T. Nakayama, T. Takashima, T. Asakawa, S. Matsumoto, D. Shimizu, M. Takahashi
Journal: Annals of Oncology (2019)
Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America
Authors: Joshua P. Metlay, Grant W. Waterer, Ann C. Long, Antonio Anzueto, Jan Brozek, Kristina Crothers, Laura A. Cooley, Nathan C. Dean, Michael J. Fine, Scott A. Flanders, Marie R. Griffin, Mark L. Metersky, Daniel M. Musher, Marcos I. Restrepo, Cynthia G. Whitney
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

Section:ChooseTop of pageAbstract <<ContentsOverviewIntroductionMethodsRecommendationsConclusionsReferencesCITING ARTICLES
Editor's Note: Hemolytic E. coli Promotes Colonic Tumorigenesis in Females
Authors: Ye Jin, Senwei Tang, Weilin Li, Siew Chien Ng, Michael W.Y. Chan, Joseph J.Y. Sung, Jun Yu
Journal: Cancer Research (2019)

The editors are publishing this note to alert readers to concerns about this article (1). In Figs. 5, 6, and 7, tissue images were used to provide evidence for the presence of tumors. Examination by the editors and original reviewers determined that the images are either of insufficient resolution to detect the presence of tumors, or that there are no tumors present. Because satisfactorily corrected figures could not be provided, the editors are publishing this note to alert readers to these concerns.
Tumour mutation burden (TMB), PD-L1, IFN-γ signaling identify subgroups of patients (pts) who benefit from durvalumab (D, anti-PDL1) or D and tremelimumab (T, anti-CTLA4) treatment in urothelial bladder cancer (UC)
Authors: C. Massard, H. Si, Q. Zhang, B. Higgs, R. Raja, S.E. Abdullah, A. Gupta, W. Li, M. van der Heijden
Journal: Annals of Oncology (2019)
Identification of two HCC phenotypes based on thrombocytopenia.
Authors: Brian I. Carr
Journal: Journal of Clinical Oncology (2012)

e14720 Background: Clinical phenotypes of small and larger HCCs are not well characterized. Aims. To characterize small HCC phenotypes. Methods: A cohort of 430 small HCCs that were diagnosed through screening, were dichotomized by size of &lt; 3cm or &gt; 3cm maximum tumor diameter and compared for radiologic and blood test parameters and analyzed by Chi-square test for categorical variables and Mann-Whitney test for continuous variables. Results: Significant differences between the tumor size groups included AFP values and platelet counts, with thrombocytopenia and elevated bilirubin levels being associated with smaller tumors. In comparing PVT+ and PVT- patients, AFP levels and platelet counts were also significantly different between the 2 groups. Conclusions: Larger tumors were associated with normal platelets and bilirubin levels, compared to smaller tumors that were more typically found in the presence of thrombocytopenia, suggesting that smaller and larger HCCs might have different developmental pathways.
Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients (pts) with metastatic urothelial carcinoma (mUC)
Authors: A. Siefker-Radtke, B. Zhong, K. Qi, W. Shalaby, P. De Porre, A. O’Hagan, P. Mahadevia, Y. Loriot
Journal: Annals of Oncology (2019)
Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis
Authors: S.C. Sasson, V.T.F. Cheung, T. Gupta, J.J. Zaunders, K. Nahar, C M-L Munier, A. Olsson-Brown, G. Ahlenstiel, U. Palendira, R.A. Scolyer, M.S. Carlino, G.V. Long, A.M. Menzies, A. Kelleher, M. Payne, B. Fairfax, M.R. Middleton, P. Klenerman, O. Brain
Journal: Annals of Oncology (2019)
Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): Subgroup analysis of the phase III OPTiM study
Authors: M.R. Middleton, K. Harrington, M. Ross, K. Ohrling, H.-S. Radcliffe, F. Collichio
Journal: Annals of Oncology (2019)
CapG promotes resistance to paclitaxel in breast cancer through transactivation of PIK3R1/P50
Authors: Yayun Chi, Jingyan Xue, Sheng Huang, Bingqiu Xiu, Yonghui Su, Wei Wang, Rong Guo, Lei Wang, Lun Li, Zhiming Shao, Wei Jin, Zhaohui Wu, Jiong Wu
Journal: Theranostics (2019)

Background: Chemotherapy resistance is a major problem in breast cancer treatment and a leading cause of mortality in breast cancer patients. Biomarkers for chemotherapy resistance is under investigation. Methods: Paclitaxel resistant cells were established and subjected to RNA sequencing. Analysis combined with two additional RNA-seq datasets was conducted. CapG expression in patients with adjuvant chemotherapy was studied in breast cancer resection specimens using IHC and related to pathological response and disease-free survival. Paclitaxel resistance was assessed by half-maximal inhibitory concentrations (IC50) and a mouse xenograft model. Results: Increased expression of actin-binding protein CapG strongly correlated with the resistance to paclitaxel chemotherapy and decreased probability to achieve pathological complete response in breast cancer patients. Overexpressing CapG significantly enhanced paclitaxel resistance in breast cancer cells and xenograft tumors. High CapG level also significantly correlated with shorter relapse-free survival as well as hyper-activation of PI3K/Akt signaling in breast cancer patients. Mechanistically, CapG enhanced PIK3R1 expression which led to increased PI3K/Akt activation. Unexpectedly, CapG was found to bind to the variant-specific promoter of PIK3R1/P50 and directly enhance its transcription. We also identified p300/CBP as a transcriptional coregulator of CapG, which is recruited to PIK3R1 promoter through interaction with CapG, thereby increasing PIK3R1/P50 transcription by enhancing histone H3K27 acetylation. Consistently, inhibiting p300/CBP substantially decreased CapG-dependent upregulation of PIK3R1/P50 and subsequent PI3K/Akt activation, resulting in increased sensitivity to paclitaxel treatment in breast cancer cells. Conclusion: High CapG levels may predict poor paclitaxel response in breast cancer patients. Targeting CapG-mediated hyperactivation of PI3K/Akt pathway may mitigate resistance to chemotherapy in breast cancer.
Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)
Authors: S. Hans, A. Simonaggio, K. Hamidatou, L. Fournier, C. Thibault, R.-T. Elaidi, S. Oudard, Y. Vano
Journal: Annals of Oncology (2019)
Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel(D), oxaliplatin(O) and S-1(S) (DOS) followed by surgery and adjuvant S-1, vs surgery and adjuvant S-1, for resectable advanced gastric cancer (GC) (PRODIGY)
Authors: Y.-K. Kang, J.H. Yook, Y.-K. Park, Y.-W. Kim, J. Kim, M.-H. Ryu, S.Y. Rha, I.-J. Chung, I.-H. Kim, S.C. Oh, C.-H. Yoo, J.-H. Choi, D.Y. Zang, G. Kim, Y. Lee, S.-H. Noh
Journal: Annals of Oncology (2019)
Retrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE
Authors: H.P. Mintz, C. Amos, R. Brannan, C. Brawley, J. Calvert, M.R. Gannon, L. Hounsome, F.C. Ingleby, S. McPhail, M.K.B. Parmar, H.M. Parsons, P. Patel, M. Rauchenberger, M.R. Sydes, H. Wu, N.D. James
Journal: Annals of Oncology (2019)
Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy
Authors: S.K. Sandhu, V.G. Atkinson, M Gonzalez Cao, T. Medina, A Soria Rivas, I. Caro, L. Roberts, Y. Song, Y. Yan, G.V. Long
Journal: Annals of Oncology (2019)
Validation of the Peak Pruritus Numerical Rating Scale
Authors: G. Yosipovitch, M. Reaney, V. Mastey, L. Eckert, A. Abbé, L. Nelson, M. Clark, N. Williams, Z. Chen, M. Ardeleanu, B. Akinlade, N.M.H. Graham, G. Pirozzi, H. Staudinger, S. Plaum, A. Radin, A. Gadkari
Journal: British Journal of Dermatology (2019)

Atopic dermatitis (AD) is a chronic skin disease occurring in about 5 to 10% of adults worldwide. It can cause intense and persistent itch. For almost two-thirds of patients with moderate-to-severe AD, the itching lasts at least 12 hours a day, and is severe to unbearable. In clinical trials that are looking at how effective a treatment for AD is, itch intensity must be measured. Given itch is subjective, its intensity is most accurately reported by patients themselves. In this study, investigators from the U.S.A. and Europe developed a scale of itch called the Peak Pruritus Numerical Rating Scale (NRS). The scale measures the worst itch (peak pruritus) during the past 24 hours by asking patients “On a scale of 0 to 10, with 0 being ‘no itch’ and 10 being ‘worst itch imaginable’, how would you rate your itch at the worst moment during the previous 24 hours?”. To ensure the scale is reliable and valid (i.e., appropriate for assessing itch in AD patients), patients were interviewed about their opinions of the scale. The scale was then implemented in three large clinical trials of adults with moderate-to-severe AD. Interviewed patients said that the scale provided a relevant, clear, and comprehensive assessment of itch severity. As hypothesized, scores from the Peak Pruritus NRS showed moderate-to-strong correlation with other measures of itch, and weak-to-moderate correlation with measures of AD signs (clinical symptoms). The investigators concluded that the Peak Pruritus NRS is a well-defined, reliable, sensitive, and valid scale for evaluating worst itch intensity in adults with moderate-to-severe AD.
Spatiotemporal intratumor genetic heterogeneity and clonal evolution in PTCs and paired DM
Authors: S. Gil Bernabé, N. Feás Rodríguez, M. Vega Herrero, J.J. Estébanez García, D. Soto de Prado, J. Fra Rodríguez, G.M. García- Rostán
Journal: Annals of Oncology (2019)
Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours
Authors: A. Stradella, M.L. Johnson, S. Goel, S.R. Chandana, M.D. Galsky, E. Calvo, V. Moreno, H. Park, H.-T. Arkenau, A. Cervantes, L Fariñas Madrid, L. Mileshkin, R. Plummer, J. Evans, L. Horvath, A. Prawira, R.J. Pelham, S. Mu, C. Andreu-Vieyra, M. Barve
Journal: Annals of Oncology (2019)
Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Commentary
Authors: D. C. Kluth, Y. Wang, Y. P. Wang, G. Zheng, V. W. S. Lee, L. Ouyang, D. H. H. Chang, D. Mahajan, J. Coombs, Y. M. Wang, S. I. Alexander, D. C. H. Harris
Journal: Kidney International (2007)
Timing to achieve complete response (CR) after definitive chemoradiotherapy (ChRT) in patients with squamous cell carcinoma of the anal (SCCAC) with and without HIV infection: A multicenter retrospective study
Authors: M.P.G. Camandaroba, S. Iseas, R.G. Taboada, C.P. Oliveira, C.D.C. Mauro, M.P. Xerfan, M. Barros, V.H.F. de Jesus, T.C. Felismino, C.A. Mello, R.P. Riechelmann
Journal: Annals of Oncology (2019)
Association between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214
Authors: V. Grünwald, T.K. Choueiri, B.I. Rini, T. Powles, S. George, M.-O. Grimm, M.B. McHenry, M. Maurer, R.J. Motzer, H.J. Hammers, N.M. Tannir, L. Albiges
Journal: Annals of Oncology (2019)
Venous thromboembolism and intracranial hemorrhage in patients with high-grade glioma
Authors: C. Borges, J. Simões, J. Reis, I. Costa, C. Lemos, P. Soares, R. Silva, B. Carvalho, C. Fernandes, A. Costa, C. Caeiro, C. Sarmento
Journal: Annals of Oncology (2019)
Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase II trial of the German Gastric Group of the AIO
Authors: S. Lorenzen, C. Pauligk, T.O. Goetze, J. Riera Knorrenschild, E. Goekkurt, F. Kullmann, D. Pink, T.J. Ettrich, N. Homann, S. Angermeier, P.C. Thuss-Patience, U. Lindig, M. Bitzer, T. Dechow, G. Schuch, H. Schmalenberg, S. Junge, R.D. Hofheinz, S.-E. Al-Batran
Journal: Annals of Oncology (2019)
Excess weight and efficacy of anti-PD-1 antibodies in advanced cancer patients
Authors: J. Rogado, N Romero Laorden, J M Sanchez Torres, A. Ramos-Levi, V.E. Pacheco-Barcia, A I Ballesteros Garcia, R. Arranz, A. Lorenzo, P. Gullon, A. Garrido, J.M. Serra, O. Donnay, M. Adrados, P. Costas, J. Aspa, A. Alfranca, R. Mondejar, R Colomer Bosch
Journal: Annals of Oncology (2019)
Nivolumab-induced and radiation recall pneumonitis in patients with non-small cell lung cancer: A multicenter real world analysis of 669 patients
Authors: N. Mamesaya, S.N. Narita, T. Naito, H. Udagawa, K. Goto, T. Miyawaki, K. Nakashima, H. Kenmotsu, T. Shimokawaji, T. Kato, T. Hakozaki, Y. Okuma, Y. Nakayama, H. Watanabe, M. Kusumoto, Y. Ohe, H. Horinouchi
Journal: Annals of Oncology (2019)
Enzalutamide (ENZA) and apalutamide (APA) In vitro chemical reactivity studies and activity in a mouse drug allergy model (MDAM)
Authors: M. Guha, C. Ji, X. Zhu, J. Whritenour, M. Hemkens, S. Tse, G.S. Walker, E. Evans, N.K. Khan, M.B. Finkelstein, E. Callegari, R.S. Obach
Journal: Annals of Oncology (2019)
NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020
Authors: Shaji K. Kumar, Natalie S. Callander, Jens Hillengass, Michaela Liedtke, Muhamed Baljevic, Erica Campagnaro, Jorge J. Castillo, Jason C. Chandler, Robert F. Cornell, Caitlin Costello, Yvonne Efebera, Matthew Faiman, Alfred Garfall, Kelly Godby, Leona Holmberg, Myo Htut, Carol Ann Huff, Yubin Kang, Ola Landgren, Ehsan Malek, Thomas Martin, James Omel, Noopur Raje, Douglas Sborov, Seema Singhal, Keith Stockerl-Goldstein, Carlyn Tan, Donna Weber, Alyse Johnson-Chilla, Jennifer Keller, Rashmi Kumar
Journal: Journal of the National Comprehensive Cancer Network (2019)

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, and multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates and changes in the 1.2020 version of the NCCN Guidelines for Multiple Myeloma.
Matters of the Mind: Honest Placebos, Hostility and Heart Attacks, and Sleepless Nights
Authors: Rita Rubin
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH)
Authors: V. Grünwald, C. Grüllich, P. Ivanyi, M. Wirth, P. Staib, M. Schostak, P. Dargatz, L. Müller, M. Metz, L. Bergmann, M.K. Welslau, P. Schütt, M.-R. Rafiyan, E. Hellmis, A. Hinke, J. Meiler, T. Kretz, W.C. Loidl, A. Flörcken, T. Steiner
Journal: Annals of Oncology (2019)